Drugs / Participants will receive single dose of 300 mg through IV infusion at Day 1
Participants will receive single dose of 300 mg through IV infusion at Day 1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05883644 | Jun 2023 → Mar 2026 overdue | hepatocellular carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Participants will receive single dose of 300 mg through IV infusion at Day 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05883644 ↗ |
| Route | Intravenous | “through IV infusion” NCT05883644 ↗ |